Purpose 3,4,3-LI(1,2-HOPO), a potent octadentate chelator of actinides, is being developed as a decorporation drug for internal contamination with radionuclides. As part of the pre-clinical program sponsored by NIH-RAID, physico-chemical characterization, HPLC method development/validation and shelf-life evaluation have been undertaken. Existing HPLC methods exhibited speciation peaks and bridging, likely due to complexation with residual metallic ions in the eluent. Derivatization of the target ligand in situ with Fe(III) chloride provided a single homogeneous iron-complex which can readily be detected and analyzed. Methods Test samples were prepared at 0.25 mg/mL in diluent containing 0.3 mg/mL FeCl3. The HPLC method used an Agilent Eclipse XDB-C18 column (150 mm x 4.6 mm, 5 µm) at 25 °C with UV detection at 280 nm. A gradient elution, with acetonitrile (11% to 100%)/buffer mobile phase, was developed for impurity profiling. The buffer consisted of 0.02% formic acid and 10 mM ammonium formate at pH 4.6. An Agilent 1200 LC-6530 Q-TOF/MS system was used to characterize the [Fe(III)-3,4,3-LI(1,2-HOPO)] derivative and the impurities.
